Kymera Therapeutics, Inc.

Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial

Kymera Therapeutics reported Q3 2026 results highlighted by positive Phase 1 healthy volunteer data for KT-579 (IRF5 degrader), which showed ≥90% median IRF5 degradation, robust suppression of inflammatory cytokines (88% TNFα, 94% IL-1β, 98% IFNβ inhibition) and a safety profile comparable to placebo. The company completed dosing in the KT-621 (STAT6) BROADEN2 Phase 2b atopic dermatitis trial, with topline data due by year-end 2026, and plans to start the KT-579 LUMORA Phase 1b lupus trial by early 2027. Financially, Kymera posted a $132.0 million net loss (EPS of -$1.32) with no collaboration revenue, versus $82.2 million net loss in Q3 2025, driven by a jump in R&D spend to $128.5 million. The balance sheet shows $1.6 billion in cash and investments, which management says funds runway into 2029 beyond multiple clinical inflection points.

•10d ago

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses

Kymera Therapeutics completed enrollment in the Phase 2b BROADEN2 trial evaluating KT-621 in atopic dermatitis, with topline data anticipated by year-end 2026. The company plans to initiate Phase 3 trials for AD by mid-2027, while the ongoing Phase 2b BREADTH trial in asthma is expected to report topline data in late 2027. Additionally, Kymera will present previously reported Phase 1b data at upcoming ERS and EADV congresses, focusing on comorbid asthma and patient-reported outcomes.

•2mo ago

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Kymera Therapeutics announced the completion of enrollment for its KT-621 BROADEN2 Phase 2b trial in atopic dermatitis nearly six months ahead of schedule, moving the topline data readout to year-end 2026. Financial results for the second quarter showed collaboration revenue of $65.0 million, driven by milestone payments from partners Gilead and Sanofi, which helped narrow the net loss to $61.2 million. The company ended the quarter with $1.5 billion in cash, providing a runway into 2029 to support Phase 3 initiations planned for mid-2027.

•3mo ago

Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer

Kymera Therapeutics appointed Terence Rooney, MD, as Chief Medical Officer to lead global clinical development strategy for its oral immunology portfolio. Rooney succeeds Jared Gollob, MD, who is retiring after eight years and will remain as an advisor through the end of the year; Rooney previously led immunology portfolio strategy at Johnson & Johnson. CEO Nello Mainolfi emphasized that Rooney's broad development experience and physician-scientist perspective make him uniquely suited to realize the full potential of the company's pipeline.

•3mo ago

Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader

Kymera Therapeutics appointed Elizabeth Laws, Ph.D., as Senior Vice President and Global Program Team Leader for KT-621, leveraging her experience leading the Dupixent franchise at Sanofi. The company confirmed KT-621 Phase 2b trials are active in atopic dermatitis and asthma, with data expected by year-end 2026 and late 2027 respectively. Kymera plans to initiate Phase 3 trials in atopic dermatitis by mid-2027 as it prepares for the next stage of development for its first-in-class oral STAT6 degrader.

•4mo ago

Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026

Kymera Therapeutics completed enrollment in the Phase 2b BROADEN2 trial evaluating KT-621 in moderate to severe atopic dermatitis. The trial enrolled nearly six months ahead of schedule, moving the topline data readout expectation to year-end 2026 from mid-2027, with Phase 3 trials now planned to initiate by mid-2027. KT-621 holds Fast Track designation for both atopic dermatitis and asthma, with data from the ongoing Phase 2b asthma trial expected in late 2027.

•4mo ago

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

Kymera Therapeutics presented Phase 1 data for its oral STAT6 degrader KT-621 in healthy Japanese adults at the Japanese Dermatological Association Annual Meeting. The study showed rapid, sustained STAT6 degradation of at least 98% at Day 7 across both dose levels, with a favorable safety profile consistent with previous non-Japanese studies. These results support the ongoing parallel Phase 2b trials in atopic dermatitis and asthma, with data expected from mid-2027 to late-2027.

•4mo ago

Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration

Kymera Therapeutics announced the first participant has been dosed in the Phase 1 trial of KT-485, an oral IRAK4 degrader for immunological diseases. The dosing event triggered a $20 million milestone payment from partner Sanofi, which is leading development and commercialization for the program outside of oncology. Kymera remains eligible for up to $975 million in additional potential milestones, with a 50/50 profit split in the US and tiered royalties in the rest of the world.

•4mo ago

Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses

Kymera Therapeutics presented new preclinical data for KT-579, its first-in-class oral IRF5 degrader, at the EULAR and FOCIS annual meetings. The data demonstrated disease-modifying activity in multiple lupus models that was comparable or superior to approved and clinically active therapies. KT-579 is currently in a Phase 1 healthy volunteer trial, with data expected in the second half of 2026, followed by a planned patient proof-of-concept trial.

•5mo ago

Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses

Kymera Therapeutics announced that Phase 1b data for its lead asset KT-621 will be featured in a late-breaking oral presentation at the Society for Investigative Dermatology (SID) Annual Meeting. The data demonstrates deep STAT6 degradation in skin and blood, along with significant downregulation of Type 2 inflammatory biomarkers and gene signatures associated with itch and fibrosis. Parallel Phase 2b trials in atopic dermatitis and asthma are ongoing, with data expected in mid-2027 and late-2027, respectively.

•5mo ago

Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week

Kymera Therapeutics presented new preclinical data at Digestive Disease Week showing its first-in-class oral IRF5 degrader KT-579 outperformed standard therapies in IBD models. The data demonstrated broad suppression of inflammatory cytokines and protection against weight loss comparable to JAK inhibitors and anti-TNF agents. The Phase 1 healthy volunteer trial for KT-579 is currently ongoing, with initial data expected in the second half of 2026. The study aims to confirm robust degradation of IRF5 at safe and well-tolerated doses. Management emphasized that KT-579's unique mechanism targets multiple disease-driving pathways simultaneously, potentially offering a convenient oral alternative to injectable biologics for complex autoimmune diseases.

•6mo ago

Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

Kymera Therapeutics reported Q1 2026 collaboration revenue of $34.4 million, a 55% increase from the prior year, driven by a $45 million milestone payment from Gilead Sciences for the exclusive license of KT-200. The FDA granted Fast Track designation to KT-621 for moderate to severe eosinophilic asthma, adding to its prior designation for atopic dermatitis, while Phase 2b trials for both indications are ongoing with data expected in 2027. The company ended the quarter with $1.55 billion in cash and investments, which it expects will fund operations into 2029, supporting the advancement of its STAT6 and IRF5 programs through multiple clinical inflection points.

•6mo ago